Alice Pharma introduced two MET inhibitors to focus on the development of lung cancer combination therapy.

Recently, OCTIMET Oncology NV, a biocomputer dedicated to the development of highly selective, differentiated MET kinase inhibitors, announced that its two exclusive interests in MET inhibitors Greater China have been granted to Allist.
, according to public information, the two candidates are OMO-1 and OMO-2, the former in clinical development and the latter in the pre-IND phase.
OMO-1 is an oral highly selective small molecule MET kinase inhibitor that has been shown to be effective in a series of preclinical cancer models.
, the product is currently in a series of clinical trials in Europe, including single-drug therapy or in a joint use with the small molecule EGFR tyrosine kinase inhibitor (TKIs).
OMO-1 has shown good safety and early efficacy in cancer patients selected for MET.
OMO-2 is a differentiated MET inhibitor with similar high selectivity and is currently being developed in pre-IND.
Under the agreement, Ales Pharmaceuticals will promote the clinical development of OMO-1 in China and focus on its joint treatment with Ales Pharmaceuticals' new cancer drug, AST2818, in the early stages of cooperation. in China, more than 38 percent of patients with non-small cell lung cancer (NSCLC) have activated EGFR mutations, and unseeded clinical needs are evident, making China an ideal place to rapidly advance expanded clinical research, according to the
press release.
is a new class 1 anti-tumor drug developed by Ales Pharmaceuticals for the third generation of EGFR-TKIs.
it can effectively distinguish between normal EGFR and EGFR/T790M variants, which inhibits normal wild type EGFR less, and greatly enhances the inhibition activity of EGFR/T790M mutations.
, candidate drugs can inhibit EGFR/T790M mutants without affecting normal EGFR activity as much as possible.
according to the Ales Pharmaceutical Bulletin, research data have shown that efluorotein is effective and safe, and shows a difference in characteristics with similar products, with the potential to become the best-in-class products.
, the product has been submitted to China in November 2019 for a new drug listing application (NDA) and has been included in the priority review.
.